mTOR-Dependent Cell Proliferation in the Brain

Larisa Ryskalin, Gloria Lazzeri, Marina Flaibani, Francesca Biagioni, Stefano Gambardella, Alessandro Frati, Francesco Fornai

Research output: Contribution to journalReview article

15 Citations (Scopus)

Abstract

The mammalian Target of Rapamycin (mTOR) is a molecular complex equipped with kinase activity which controls cell viability being key in the PI3K/PTEN/Akt pathway. mTOR acts by integrating a number of environmental stimuli to regulate cell growth, proliferation, autophagy, and protein synthesis. These effects are based on the modulation of different metabolic pathways. Upregulation of mTOR associates with various pathological conditions, such as obesity, neurodegeneration, and brain tumors. This is the case of high-grade gliomas with a high propensity to proliferation and tissue invasion. Glioblastoma Multiforme (GBM) is a WHO grade IV malignant, aggressive, and lethal glioma. To date, a few treatments are available although the outcome of GBM patients remains poor. Experimental and pathological findings suggest that mTOR upregulation plays a major role in determining an aggressive phenotype, thus determining relapse and chemoresistance. Among several activities, mTOR-induced autophagy suppression is key in GBM malignancy. In this article, we discuss recent evidence about mTOR signaling and its role in normal brain development and pathological conditions, with a special emphasis on its role in GBM.

Original languageEnglish
Pages (from-to)7082696
JournalBioMed Research International
Volume2017
DOIs
Publication statusPublished - 2017

Fingerprint

Cell proliferation
Sirolimus
Brain
Cell Proliferation
Glioblastoma
Autophagy
Glioma
Up-Regulation
Cell growth
Metabolic Networks and Pathways
Phosphatidylinositol 3-Kinases
Brain Neoplasms
Tumors
Cell Survival
Phosphotransferases
Obesity
Cells
Modulation
Tissue
Phenotype

Keywords

  • Journal Article
  • Review

Cite this

mTOR-Dependent Cell Proliferation in the Brain. / Ryskalin, Larisa; Lazzeri, Gloria; Flaibani, Marina; Biagioni, Francesca; Gambardella, Stefano; Frati, Alessandro; Fornai, Francesco.

In: BioMed Research International, Vol. 2017, 2017, p. 7082696.

Research output: Contribution to journalReview article

@article{27a0951fe6af44309abaf98e0edd2fee,
title = "mTOR-Dependent Cell Proliferation in the Brain",
abstract = "The mammalian Target of Rapamycin (mTOR) is a molecular complex equipped with kinase activity which controls cell viability being key in the PI3K/PTEN/Akt pathway. mTOR acts by integrating a number of environmental stimuli to regulate cell growth, proliferation, autophagy, and protein synthesis. These effects are based on the modulation of different metabolic pathways. Upregulation of mTOR associates with various pathological conditions, such as obesity, neurodegeneration, and brain tumors. This is the case of high-grade gliomas with a high propensity to proliferation and tissue invasion. Glioblastoma Multiforme (GBM) is a WHO grade IV malignant, aggressive, and lethal glioma. To date, a few treatments are available although the outcome of GBM patients remains poor. Experimental and pathological findings suggest that mTOR upregulation plays a major role in determining an aggressive phenotype, thus determining relapse and chemoresistance. Among several activities, mTOR-induced autophagy suppression is key in GBM malignancy. In this article, we discuss recent evidence about mTOR signaling and its role in normal brain development and pathological conditions, with a special emphasis on its role in GBM.",
keywords = "Journal Article, Review",
author = "Larisa Ryskalin and Gloria Lazzeri and Marina Flaibani and Francesca Biagioni and Stefano Gambardella and Alessandro Frati and Francesco Fornai",
year = "2017",
doi = "10.1155/2017/7082696",
language = "English",
volume = "2017",
pages = "7082696",
journal = "BioMed Research International",
issn = "2314-6133",
publisher = "Hindawi Publishing Corporation",

}

TY - JOUR

T1 - mTOR-Dependent Cell Proliferation in the Brain

AU - Ryskalin, Larisa

AU - Lazzeri, Gloria

AU - Flaibani, Marina

AU - Biagioni, Francesca

AU - Gambardella, Stefano

AU - Frati, Alessandro

AU - Fornai, Francesco

PY - 2017

Y1 - 2017

N2 - The mammalian Target of Rapamycin (mTOR) is a molecular complex equipped with kinase activity which controls cell viability being key in the PI3K/PTEN/Akt pathway. mTOR acts by integrating a number of environmental stimuli to regulate cell growth, proliferation, autophagy, and protein synthesis. These effects are based on the modulation of different metabolic pathways. Upregulation of mTOR associates with various pathological conditions, such as obesity, neurodegeneration, and brain tumors. This is the case of high-grade gliomas with a high propensity to proliferation and tissue invasion. Glioblastoma Multiforme (GBM) is a WHO grade IV malignant, aggressive, and lethal glioma. To date, a few treatments are available although the outcome of GBM patients remains poor. Experimental and pathological findings suggest that mTOR upregulation plays a major role in determining an aggressive phenotype, thus determining relapse and chemoresistance. Among several activities, mTOR-induced autophagy suppression is key in GBM malignancy. In this article, we discuss recent evidence about mTOR signaling and its role in normal brain development and pathological conditions, with a special emphasis on its role in GBM.

AB - The mammalian Target of Rapamycin (mTOR) is a molecular complex equipped with kinase activity which controls cell viability being key in the PI3K/PTEN/Akt pathway. mTOR acts by integrating a number of environmental stimuli to regulate cell growth, proliferation, autophagy, and protein synthesis. These effects are based on the modulation of different metabolic pathways. Upregulation of mTOR associates with various pathological conditions, such as obesity, neurodegeneration, and brain tumors. This is the case of high-grade gliomas with a high propensity to proliferation and tissue invasion. Glioblastoma Multiforme (GBM) is a WHO grade IV malignant, aggressive, and lethal glioma. To date, a few treatments are available although the outcome of GBM patients remains poor. Experimental and pathological findings suggest that mTOR upregulation plays a major role in determining an aggressive phenotype, thus determining relapse and chemoresistance. Among several activities, mTOR-induced autophagy suppression is key in GBM malignancy. In this article, we discuss recent evidence about mTOR signaling and its role in normal brain development and pathological conditions, with a special emphasis on its role in GBM.

KW - Journal Article

KW - Review

U2 - 10.1155/2017/7082696

DO - 10.1155/2017/7082696

M3 - Review article

VL - 2017

SP - 7082696

JO - BioMed Research International

JF - BioMed Research International

SN - 2314-6133

ER -